Business
Result of General Meeting
Result of General Meeting.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 6018S Sareum Holdings PLC 22 December 2016 \n\nSAREUM HOLDINGS PLC\n(\"Sareum\" or \"the Company\")\nResult of General Meeting\nSareum (AIM: SAR), the specialist cancer drug discovery and development business, announces that at the General Meeting held earlier today, the resolution was duly passed.\nFor further information:\n\n\n\n\nSareum Holdings plc\n\n\n \n\n\n\n\nTim Mitchell\n\n\n01223 497 700\n\n\n\n\nWH Ireland Limited (Nominated Adviser and Co-Broker)\n\n\n\n\nChris Fielding / Nick Prowting\n\n\n020 7220 1666\n\n\n\n\nHybridan LLP (Co-Broker)\n\n\n \n\n\n\n\nClaire Noyce / William Lynne\n\n\n020 3764 2341/2342\n\n\n\n\nThe Communications Portfolio (Media enquiries)\n\n\n \n\n\n\n\nAriane Comstive\[email protected] \n\n\n07785 922 354\n\n\n\n\nNotes for editors:\nSareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.\nSareum operates an outsourced research model, working with international collaborators and a world-wide network of research providers. Its most advanced programme (Chk1) commenced clinical trials in May 2016 and was licensed to NASDAQ-listed ProNAi Therapeutics in September 2016.\nSKIL(R) (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3 and TYK2 kinase cancer and autoimmune disease research programmes, which are in the IND-enabling preclinical and lead optimisation stages respectively. SKIL(R) can also generate drug research programmes against other kinase targets.\nSareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit www.sareum.co.uk\n\nThis information is provided by RNSThe company news service from the London Stock Exchange END ROMLIFSAFRLFFIR\n ","length":3319,"tagName":"div"}]